معرفی
Brian Shinder, MD is an Assistant Professor in the Department of Urology at Yale School of Medicine, with clinical appointments at Yale Cancer Center and Smilow Cancer Hospital. His primary clinical focus is urologic oncology, specializing in the treatment of kidney, prostate, and bladder cancers using both minimally invasive and traditional surgical approaches.
- Yale School of Medicine, Department of Urology
- Prostate & Urologic Cancers Program
- Urologic Oncology Division
- Yale Cancer Center
Dr. Shinder's research interests center on renal cell carcinoma with particular emphasis on genetic markers, metastatic patterns, and clinical trial participation disparities. His work explores how molecular markers can improve diagnosis and treatment selection, while also investigating barriers to clinical trial enrollment for patients with kidney and prostate cancers. He notes that urology has been at the forefront of robotic surgery and continues to push boundaries in surgical technology and genetic applications for cancer treatment.
His recent publications demonstrate a strong focus on renal cell carcinoma research, with multiple publications examining metastatic patterns (including rare sites like cardiac and testicular metastases), predictive biomarkers, and factors affecting clinical trial participation. His work shows particular attention to healthcare disparities in cancer research participation.
- ASCO Conquer Cancer Young Investigator Award (2023)
Dr. Shinder is actively engaged in clinical research and patient care, with frequent collaborations with Dr. Isaac Y. Kim and Dr. Joshua Sterling. His educational background includes an MD from Rutgers Robert Wood Johnson Medical School, a urologic oncology fellowship at Memorial Sloan Kettering Cancer Center, and residency training in urology at Rutgers Robert Wood Johnson Medical School. He is a member of both the American Urologic Association and the Society of Urologic Oncology since 2017.
